{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:50:24Z","timestamp":1790736624222,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2026.104684","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:44:26Z","timestamp":1775231066000},"page":"104684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6614","authenticated-orcid":false,"given":"Maria-Pilar","family":"Barretina-Ginesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7257-5642","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-7583","authenticated-orcid":false,"given":"Alfonso","family":"Cort\u00e9s-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"P\u00e9rez-Mies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-8396","authenticated-orcid":false,"given":"Laia","family":"Valls-Masot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5162-7247","authenticated-orcid":false,"given":"Marina","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104684_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.104684_bib4","article-title":"Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104684_bib5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104684_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ijgc.2026.104684_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104684_bib10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104684_bib11","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A Phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.ijgc.2026.104684_bib12","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, Phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2021.02.031","article-title":"The role of blinded independent radiologic review in ovarian cancer clinical trials: discerning the value","volume":"161","author":"Loreen","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104684_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.acra.2017.04.014","article-title":"Applying quantitative CT image feature analysis to predict response of ovarian cancer patients to chemotherapy","volume":"24","author":"Danala","year":"2017","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1109\/TMI.2015.2473823","article-title":"A new approach to evaluate drug treatment response of ovarian cancer patients based on deformable image registration","volume":"35","author":"Tan","year":"2016","journal-title":"IEEE Trans Med Imaging"},{"issue":"suppl 2","key":"10.1016\/j.ijgc.2026.104684_bib16","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.acra.2023.04.036","article-title":"Predicting neoadjuvant chemotherapy response and high-grade serous ovarian cancer from CT images in ovarian cancer with multitask deep learning: a multi-center study","volume":"30","author":"Yin","year":"2023","journal-title":"Acad Radiol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/IGC.0000000000000361","article-title":"Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer","volume":"25","author":"Rizzuto","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13027-022-00441-3","article-title":"Diffusion weighted imaging and diffusion kurtosis imaging in abdominal oncological setting: why and when","volume":"17","author":"Granata","year":"2022","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1148\/radiol.2019190545","article-title":"Diffusion-weighted MRI in advanced epithelial ovarian cancer: apparent diffusion coefficient as a response marker","volume":"293","author":"Winfield","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12885-023-10760-2","article-title":"Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer","volume":"23","author":"Reijonen","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib21","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.acra.2020.01.024","article-title":"Prediction of platinum-based chemotherapy response in advanced high-grade serous ovarian cancer: ADC histogram analysis of primary tumors","volume":"28","author":"Lu","year":"2021","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47195-4","article-title":"Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer","volume":"9","author":"Deen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijgc.2026.104684_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.895177","article-title":"Deep learning magnetic resonance imaging predicts platinum sensitivity in patients with epithelial ovarian cancer","volume":"12","author":"Lei","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104684_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/RLU.0000000000002227","article-title":"The prognostic value of 18F-FDG PET\/CT in monitoring chemotherapy in ovarian cancer both at initial diagnosis and at recurrent disease","volume":"43","author":"Rubello","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104684_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.diii.2021.05.007","article-title":"Diffusion-weighted MRI and PET\/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy","volume":"102","author":"Cromb\u00e9","year":"2021","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib26","first-page":"81","article-title":"18F.FDG-PET\/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy","volume":"55","author":"Martoni","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib27","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00259-020-05092-3","article-title":"Predicting tumor response and outcome of second-look surgery with 18F-FDG PET\/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer","volume":"48","author":"Aide","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib28","first-page":"1211","article-title":"Early assessment of response to neoadjuvant chemotherapy with 18F-FDG-PET\/CT in patients with advanced-stage ovarian cancer","volume":"52","author":"Chung","year":"2020","journal-title":"Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib29","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3802\/jgo.2022.33.e28","article-title":"Prognostic value of complete metabolic response on 18F-FDG-PET\/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer","volume":"33","author":"Chung","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","article-title":"18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"140","author":"Vallius","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104684_bib31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-018-3961-z","article-title":"18F-FDG-PET\/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer","volume":"45","author":"Vallius","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijgc.2026.104684_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejrad.2017.05.036","article-title":"F-18 FDG PET\/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer","volume":"93","author":"Gallicchio","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ijgc.2026.104684_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1341228","article-title":"Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI","volume":"14","author":"Na","year":"2024","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104684_bib34","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.ejso.2022.08.026","article-title":"Response to treatment and prognostic significance of supradiaphragmatic disease in patients with high-grade serous ovarian cancer","volume":"48","author":"Leone Roberti Maggiore","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41747-023-00364-7","article-title":"Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers","volume":"7","author":"Hatamikia","year":"2023","journal-title":"Eur Radiol Exp"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib36","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s00261-020-02820-z","article-title":"Radiomics and radiogenomics in ovarian cancer: a literature review","volume":"46","author":"Nougaret","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104684_bib37","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.3390\/cancers15245827","article-title":"Imaging of peritoneal carcinomatosis in advanced ovarian cancer: CT, MRI, radiomic features and resectability criteria","volume":"15","author":"Miceli","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib38","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00330-022-09180-w","article-title":"Ovarian imaging radiomics quality score assessment: an EuSoMII radiomics auditing group initiative","volume":"33","author":"Ponsiglione","year":"2023","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib39","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers15061823","article-title":"CA-125 early dynamics to predict overall survival in women with newly diagnosed advanced ovarian cancer based on meta-analysis data","volume":"15","author":"Karamouza","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib42","doi-asserted-by":"crossref","first-page":"pkaa026","DOI":"10.1093\/jncics\/pkaa026","article-title":"Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (ICON-7)","volume":"4","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"34","key":"10.1016\/j.ijgc.2026.104684_bib43","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA\/GOG-3005 study","volume":"41","author":"You","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ijgc.2026.104684_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e17547","article-title":"Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant\/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC)","volume":"41","author":"Hannaway","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104684_bib46","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/cancers16132339","article-title":"Prognostic role of CA-125 elimination rate constant (KELIM) in patients with advanced epithelial ovarian cancer who received PARP inhibitors","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijgc.2026.104684_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2025.02.016","article-title":"Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery","volume":"195","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104684_bib48","doi-asserted-by":"crossref","first-page":"19449","DOI":"10.1002\/cam4.6546","article-title":"Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004)","volume":"12","author":"Kim","year":"2023","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104684_bib49","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","article-title":"Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU Study","volume":"25","author":"Colomban","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104684_bib50","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ijgc-2023-004825","article-title":"Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis","volume":"33","author":"Kim","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib51","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3802\/jgo.2024.35.e34","article-title":"Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a \u201creal-life setting\u201d","volume":"35","author":"van Wagensveld","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2022.10.014","article-title":"Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer","volume":"167","author":"Piedimonte","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104684_bib53","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the Phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104684_bib54","article-title":"562 Benefit from atezolizumab in patients with a poor prognostic ovarian cancer in first-line setting: IMAGYN-050 trial","author":"You","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104684_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073758","article-title":"Optimising HIV care using information obtained from Proms: protocol for an observational study","volume":"13","author":"Moody","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib56","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/jcm12062155","article-title":"Chemotherapy response score in ovarian cancer patients: an overview of its clinical utility","volume":"12","author":"Rodolakis","year":"2023","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104684_bib57","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ijgc-2018-000092","article-title":"Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results","volume":"29","author":"B\u00f6hm","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a Chemotherapy Response Score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2026.104684_bib61","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/S0090-8258(22)01710-3","article-title":"Tissue is the issue: chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC) (488)","volume":"166","author":"Knickerbocker","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib62","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.ygyno.2023.06.126","article-title":"Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)","volume":"176","author":"Piedimonte","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1971","article-title":"793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)","volume":"34","author":"Catana","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib65","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e73","article-title":"Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and\/or maintenance therapy","volume":"35","author":"Lee","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib66","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/diagnostics12030633","article-title":"Prognostic value of Chemotherapy Response Score (CRS) assessed on the adnexa in ovarian high-grade serous carcinoma: a systematic review and meta-analysis","volume":"12","author":"Santoro","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104684_bib67","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic value of pathologic chemotherapy response score in patients with ovarian cancer after neoadjuvant chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib68","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAS.0000000000001391","article-title":"A 3-tier chemotherapy response score for ovarian\/Fallopian tube\/peritoneal high-grade serous carcinoma: is it clinically relevant?","volume":"44","author":"Lawson","year":"2020","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-020-6688-8","article-title":"Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104684_bib70","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ijgc-2021-003116","article-title":"BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score","volume":"32","author":"Ergasti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104684_bib71","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1200\/JCO.2023.41.16_suppl.5591","article-title":"The role of Chemotherapy Response Score (CRS) in the decision making process for patients with advanced high grade serous ovarian cancer undergoing neoadjuvant chemotherapy","volume":"41","author":"Marchetti","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2022.02.006","article-title":"Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer","volume":"165","author":"LaFargue","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104684_bib73","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/jpm11070612","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"11","author":"Wagener-Ryczek","year":"2021","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104684_bib74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/jpm13020284","article-title":"Homologous recombination deficiency in ovarian cancer: from the biological rationale to current diagnostic approaches","volume":"13","author":"Mangogna","year":"2023","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104684_bib75","article-title":"Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes","volume":"4","author":"Cunnea","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijgc.2026.104684_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1240068","article-title":"A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score","volume":"14","author":"Yang","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.ijgc.2026.104684_bib77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ygyno.2023.11.027","article-title":"HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma","volume":"180","author":"Koskela","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2023.01.026","article-title":"A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer","volume":"171","author":"Blanc-Durand","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"suppl 12","key":"10.1016\/j.ijgc.2026.104684_bib79","first-page":"P1","article-title":"Abstract P1-01-18: Prevalence of functional HRD by the RAD51 assay: a pooled analysis with 367 patients from BRCA-associated tumor types","volume":"31","author":"Villacampa","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"823","key":"10.1016\/j.ijgc.2026.104684_bib80","doi-asserted-by":"crossref","first-page":"A312","DOI":"10.1136\/ijgc-2023-ESGO.654","article-title":"#823 Comprehensive characterization of na\u00efve treatment samples of high grade serous ovarian cancer addressed to neoadjuvant chemotherapy: a hypothesis-generating study on biomarkers of response to platinum-based chemotherapy","volume":"33","author":"Trozzi","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib81","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"7553","key":"10.1016\/j.ijgc.2026.104684_bib82","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1757-2215-6-2","article-title":"Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer","volume":"6","author":"Gunn","year":"2013","journal-title":"J Ovarian Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-021-04301-6","article-title":"Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients","volume":"88","author":"Sokolenko","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"37","key":"10.1016\/j.ijgc.2026.104684_bib85","doi-asserted-by":"crossref","first-page":"62240","DOI":"10.18632\/oncotarget.19272","article-title":"CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance","volume":"8","author":"Sapoznik","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib86","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cjp2.168","article-title":"Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma","volume":"6","author":"Chan","year":"2020","journal-title":"J Pathol Clin Res"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104684_bib87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/cncr.34582","article-title":"CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study","volume":"129","author":"Kang","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ijgc.2026.104684_bib88","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/j.annonc.2023.09.1952","article-title":"774P CCNE1 amplification defines a good prognostic subgroup among BRCAwt\/HRDneg advanced high-grade ovarian cancer (HGOC)","volume":"34","author":"Blanc-Durand","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib89","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104684_bib90","doi-asserted-by":"crossref","first-page":"PR-003","DOI":"10.1158\/1538-7445.OVARIAN23-PR-003","article-title":"Abstract PR-003: Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive","volume":"84","author":"Pikkusaari","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104684_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.581534","article-title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced ovarian cancer","volume":"27","author":"Shen","year":"2021","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104684_bib92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13048-020-00729-1","article-title":"Prediction of the treatment response in ovarian cancer: a ctDNA approach","volume":"13","author":"Sharbatoghli","year":"2020","journal-title":"J Ovarian Res"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104684_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib94","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib95","first-page":"2713","article-title":"Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer","volume":"19","author":"Noguchi","year":"2020","journal-title":"Oncol Lett."},{"key":"10.1016\/j.ijgc.2026.104684_bib96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Lett"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104684_bib97","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3390\/cancers14246030","article-title":"The role of circulating tumor cells in ovarian cancer dissemination","volume":"14","author":"Szczerba","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib98","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/inm.12964","article-title":"The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: a systematic review and meta-analysis","volume":"31","author":"Okoli","year":"2022","journal-title":"Int J Ment Health Nurs"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104684_bib99","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.25602","article-title":"Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients","volume":"128","author":"Wimberger","year":"2011","journal-title":"Int J Cancer"},{"issue":"63","key":"10.1016\/j.ijgc.2026.104684_bib100","doi-asserted-by":"crossref","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104684_bib101","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104684_bib102","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s12094-024-03531-3","article-title":"SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)","volume":"26","author":"Perez-Fidalgo","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104684_bib103","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104684_bib104","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104684_bib105","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e57","article-title":"Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus","volume":"34","author":"Redondo","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2023.05.065","article-title":"Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: results of a Delphi study","volume":"175","author":"Colombo","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104684_bib107","article-title":"Predictive value of machine learning for platinum chemotherapy responses in ovarian cancer: systematic review and meta-analysis","volume":"26","author":"Wang","year":"2024","journal-title":"J Med Internet Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:34:45Z","timestamp":1780306485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2600215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X2600215X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104684","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104684"}}